http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021018414-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b0ab47985988abd16331e7a683b2490 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90c5874c11e78d82848e5f76682f670f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd1bf7e8d7fa187401e57cec7b80a7f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ba6fac3b78454a2bb5e72fc1e023d59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04fbb570b74bd909bbcf66f0093e6239 |
| publicationDate | 2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021018414-A1 |
| titleOfInvention | Pharmaceutical composition comprising dabigatran etexilate |
| abstract | The present invention is related to a pharmaceutical composition for oral administration comprising a core comprising a pharmaceutically acceptable organic acid; optionally an isolating layer comprising a pharmaceutically acceptable polymer; and an active substance layer comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof and a binder; wherein weight ratio between the pharmaceutically acceptable organic acid and the active substance is comprised between 0.15:1 and 0.40:1, and wherein the weight of active substance in said ratio is expressed as equivalent weight of dabigatran etexilate mesylate. The invention also relates to a method of preparation of this pharmaceutical composition and its use in the treatment and/or prevention of blood coagulation, thromboembolic events and stroke. |
| priorityDate | 2019-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.